PENG vs FICB Anesthesia for Hip Fracture
Trial Summary
What is the purpose of this trial?
This trial compares two methods of numbing the hip area in elderly patients with hip fractures. These methods aim to reduce pain and may be more effective and safer than traditional pain medications.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment PENG block for hip fracture?
Is PENG or FICB anesthesia safe for humans?
How does the PENG vs FICB treatment for hip fracture differ from other treatments?
The PENG (Pericapsular Nerve Group) Block and FICB (Fascia Iliaca Compartment Block) are unique because they are nerve block techniques used to manage pain in hip fractures, offering a less invasive alternative to traditional surgical methods. These blocks target specific nerves to provide pain relief, potentially reducing the need for systemic pain medications and their associated side effects.678910
Research Team
Eligibility Criteria
This trial is for emergency department patients with hip fractures, specifically femoral neck or intertrochanteric fractures. Participants must consent to the procedure and not have allergies to local anesthetics. Those with severe injuries causing instability, serious unstable medical conditions, or hemodynamic instability cannot join.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either the PENG block or FICB for pain control in the emergency department
Follow-up
Participants are monitored for pain control and opioid use until surgery or up to 24 hours
Treatment Details
Interventions
- FICB (Procedure)
- PENG (Procedure)
FICB is already approved in Canada for the following indications:
- Pain management for hip fractures and hip surgery
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Virginia
Lead Sponsor
James E. Ryan
University of Virginia
Chief Executive Officer since 2018
J.D. from Harvard Law School
Nikki Hastings
University of Virginia
Chief Medical Officer since 2018
Ph.D. in Biomedical Engineering from University of Virginia